Last checked at 5 Oct 2017 07:00
Scrip Dividend - total issued shares
Reading, United Kingdom (5 October 2017)
On 3 August 2017 ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.4 cents per share (the "interim dividend"). This interim dividend is to be paid on 20 October 2017 to shareholders on the share register as at 8 September 2017 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 11 September 2017 the Company announced that a scrip dividend scheme will be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend scheme was announced on 14 September.
It is confirmed that 377,948 ordinary shares of 10 pence each will be allotted and issued on 20 October 2017 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.
Dealings in the share issued under the scrip dividend scheme is expected to commence on 20 October 2017.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the interim dividend are:
Ex-dividend Date | 7 September 2017 |
Record Date | 8 September 2017 |
Scrip calculation price determined | 7-13 September 2017 (inclusive) |
Scrip calculation price available and announced | 14 September 2017 |
Mandate delivery deadline for Shares held in uncertificated form | 3.00 p.m. on 29 September 2017 |
Mandate delivery deadline for Shares held in certificated form | 5.00 p.m. on 29 September 2017 |
Announcement of the total amount of new shares to be issued | 5 October 2017 |
Dividend payment date | 20 October 2017 |
Dispatch of statement in accordance with section 7 of Scheme Rules and share certificates, CREST accounts credited/updated, and first day of dealings in New Shares | 20 October 2017 |
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, ConvaTec +44 (0)7470 909 582
investorrelations@convatec.com
Legal Entity Identifier Code 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #